5-Dimethylaminocytidin | 51391-95-8

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 5-Dimethylaminocytidin
• 英文别名: 5-dimethylamino-cytidine；4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(dimethylamino)pyrimidin-2-one
• CAS: 51391-95-8
• 化学式: C₁₁H₁₈N₄O₅
• 分子量: 286.288
• InChiKey: JSSKXWINFDBOFC-FDDDBJFASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.1
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  132
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  5-Dimethylaminocytidin 在 2-乙酰氧基异丁酰氯 作用下， 以 乙腈 为溶剂， 生成 (3aS)-7-dimethylamino-2t-hydroxymethyl-6-imino-(3ar,9ac)-2,3,3a,9a-tetrahydro-6H-furo[2',3':4,5]oxazolo[3,2-a]pyrimidin-3c-ol
  参考文献：
  名称：

  2-酰氧基异丁酰卤化物与核苷的反应。V.与胞苷及其衍生物的反应；

  摘要：

  DOI：

  10.1021/jo00929a009

文献信息

• Chemically modified messenger RNA's
  申请人：Novartis AG

  公开号：US11377656B2

  公开（公告）日：2022-07-05

  This invention provides messenger RNA (mRNA) molecules comprising an open reading frame that encodes a protein of interest, wherein said modified RNA comprises a modified nucleoside selected from the group consisting of: (I), (II), and (III), gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of mRNA molecules.

  本发明提供了信使 RNA（mRNA）分子，该分子包含编码感兴趣的蛋白质的开放阅读框，其中所述修饰的 RNA 包含选自由(Ⅰ)、(Ⅱ)和(Ⅲ)组成的组的修饰核苷、包含该分子的基因治疗载体、合成该分子的方法，以及包含该分子的基因替换、基因治疗、基因转录沉默和向体内组织递送治疗蛋白质的方法。本发明还提供了降低 mRNA 分子免疫原性的方法。
• CHEMICALLY MODIFIED MESSENGER RNA'S
  申请人：Novartis AG

  公开号：US20190100752A1

  公开（公告）日：2019-04-04

  This invention provides messenger RNA (mRNA) molecules comprising an open reading frame that encodes a protein of interest, wherein said modified RNA comprises a modified nucleoside selected from the group consisting of: (I), (II), and (III), gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of mRNA molecules.